Gradiant Wins New Water Contracts for Major US Semiconductor Fabs in New York, Virginia, Idaho, and Utah

Table

Gradiant today announced $300 million in new contracts from semiconductor manufacturing customers since the start of 2026.

$300 million in new ultrapure water, wastewater, and zero liquid discharge contracts mark continued commercial momentum in the chips layer of the AI economy

BOSTON, Sept 17 (Bernama-BUSINESS WIRE) — Gradiant, the water layer of the AI economy, today announced $300 million in new contracts from semiconductor manufacturing customers since the start of 2026, reflecting strong commercial momentum in a sector where water security is becoming a critical enabler of scale and speed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915041166/en/

Among the wins, Gradiant secured new contracts with several leading global semiconductor manufacturers across five fabrication sites in New York, Virginia, Idaho, and Utah. The projects include ultrapure water (UPW), high-recovery wastewater treatment, local scrubber reclaim, and zero liquid discharge (ZLD) systems designed to reduce freshwater demand, increase water reuse, and maximize production in increasingly water-constrained environments.

Rather than serving a single point in the water cycle, Gradiant will deliver its full semiconductor portfolio across these sites — from ultrapure water production to high-recovery wastewater treatment, scrubber reclaim, treatment of complex streams such as hydrofluoric-acid wastewater, and zero liquid discharge. Several of the awards are repeat contracts from existing customers, including the second phase of a high-recovery wastewater facility at one of the world’s largest semiconductor fabs and a scrubber reclaim design, already proven for the same customer in Singapore, Taiwan, and the U.S., that recovers more than 80 percent of feed volume.

“Water has become one of the defining constraints on how quickly the world can build the chips powering AI data centers, including high-bandwidth memory,” said Prakash Govindan, CEO of Gradiant. “That’s why leading semiconductor manufacturers keep choosing Gradiant: we own the full water cycle, from ultrapure water to the most complex wastewater streams, as one accountable partner. Water will not be the reason a fab falls behind.”

“These wins are exactly the kind of momentum we need to reach our target of a $1 billion U.S. order book next year,” said Nish Vora, Managing Director, Americas at Gradiant. “Each of these contracts reinforces Gradiant’s position as the water layer for semiconductors, eliminating water as a constraint for the companies building the chips the AI economy runs on.”

From ultrapure water and advanced wastewater treatment to high-recovery water reuse and ZLD systems, Gradiant’s semiconductor solutions are designed to help manufacturers increase capacity while reducing water consumption and environmental impact. As investment in AI infrastructure continues to accelerate, water management is becoming a critical enabler of how fast the next generation of semiconductor fabs can scale.

About Gradiant

Gradiant is the Water Layer of the AI Economy. Founded at MIT and headquartered in Boston, Gradiant builds the water and wastewater infrastructure behind AI’s build-out, from chips and data centers to the energy and industries that depend on them. As AI demand accelerates, water is becoming the resource that determines what can be built. Gradiant’s technologies reduce what industry withdraws, reclaim what it would waste, and renew clean water to nature, with more than 3,000 treatment plants built across 92 countries. Learn more at gradiant.com.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20260915041166/en/

Contact

Corporate Contact
Felix Wang
Gradiant, Global Head of Marketing
fwang@gradiant.com

Source : Gradiant

GLOBAL WEALTH MIGRATION DRIVEN BY RISING PRIVATE HEALTHCARE COSTS – HENLEY & PARTNERS

KUALA LUMPUR, Dec 9 (Bernama) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and price of reliable private care a key factor for high-net-worth families deciding where to live, invest, or secure residence and citizenship.

New data released by Henley & Partners confirms record demand for cross-border planning and highlights healthcare cost exposure as a critical “hidden variable” shaping long-term destination choices for globally mobile families.

The firm in a statement said it has received applications from 92 nationalities this year and supported demand across more than 50 residence and citizenship programmes and has assisted applicants from 136 nationalities over the past five years.

Comparing the first three quarters of 2024 with the same period in 2025, Henley & Partners reported a 43 per cent increase in applications, underscoring intensifying cross-border mobility among affluent households.

To support destination planning, the firm is referencing the newly published SIP Health Cost Index (HCI) 2025—a benchmark of the true cost of private healthcare across 50 key countries, based on International Private Medical Insurance (IPMI) premiums.

While Henley & Partners focuses on residence and citizenship advisory, the Index provides a complementary view into how private healthcare costs can materially affect a destination’s long-term affordability and suitability, especially for families with children, ageing parents, or elective cross-border medical needs.

The Index identifies familiar high-cost markets, with the United States ranking as the world’s most expensive private healthcare market, with an average annual IPMI-based cost of US$17,969 per person, followed by Hong Kong and Singapore. (US$1 = RM4.11)

However, unexpected shifts are emerging beyond traditional hubs. Several markets in emerging Asia—including China, Thailand, and Taiwan—have now entered the global top 12 for private-care costs, driven by strong demand for premium hospitals and rising inpatient expenses.

Europe shows one of the widest spreads, with the United Kingdom (UK), Greece, and Spain among its most expensive markets, partly due to Insurance Premium Tax in the UK and Greece. In the Middle East, the United Arab Emirates ranks 10th globally, reflecting expanding high-end healthcare infrastructure and medical-tourism ambitions.

As global wealth migration continues to rise, Henley & Partners said private healthcare cost exposure is becoming a first-order consideration in residence and citizenship planning. The SIP Health Cost Index provides a practical comparison tool to help families anticipate long-term healthcare budgets and avoid hidden high-cost risks when choosing a home, second residence, or multi-base lifestyle.

— BERNAMA

ZENAS BIOPHARMA TO PARTICIPATE IN UPCOMING HEALTHCARE INVESTOR CONFERENCES

WALTHAM, Mass, 8 Nov (Bernama-GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences:

  • Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
  • Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
  • Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
  • Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL

Live webcasts and archived replays of the Company’s presentations at the Jefferies, Citi and Evercore conferences can be accessed under “Events and Presentations” in the Investors and Media section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com

SOURCE : Zenas BioPharma (USA) LLC